SG10202113199RA - Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine - Google Patents
Dementia therapeutic agent combining pyrazoloquinoline derivative and memantineInfo
- Publication number
- SG10202113199RA SG10202113199RA SG10202113199RA SG10202113199RA SG10202113199RA SG 10202113199R A SG10202113199R A SG 10202113199RA SG 10202113199R A SG10202113199R A SG 10202113199RA SG 10202113199R A SG10202113199R A SG 10202113199RA SG 10202113199R A SG10202113199R A SG 10202113199RA
- Authority
- SG
- Singapore
- Prior art keywords
- memantine
- therapeutic agent
- agent combining
- dementia therapeutic
- pyrazoloquinoline derivative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762513754P | 2017-06-01 | 2017-06-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10202113199RA true SG10202113199RA (en) | 2021-12-30 |
Family
ID=64454745
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202113199RA SG10202113199RA (en) | 2017-06-01 | 2018-05-30 | Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine |
| SG11201909590X SG11201909590XA (en) | 2017-06-01 | 2018-05-30 | Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201909590X SG11201909590XA (en) | 2017-06-01 | 2018-05-30 | Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11147803B2 (en) |
| EP (1) | EP3632437B1 (en) |
| JP (1) | JP7177772B2 (en) |
| KR (1) | KR102627790B1 (en) |
| CN (1) | CN110603039B (en) |
| AU (1) | AU2018276568A1 (en) |
| BR (1) | BR112019023595A2 (en) |
| CA (1) | CA3060183A1 (en) |
| IL (1) | IL270394B (en) |
| MX (1) | MX2019013383A (en) |
| SG (2) | SG10202113199RA (en) |
| WO (1) | WO2018221550A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3059539A1 (en) | 2017-06-01 | 2018-12-06 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition comprising pde9 inhibitor |
| SG10202113198TA (en) | 2017-06-01 | 2021-12-30 | Eisai R&D Man Co Ltd | Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil |
| AU2018278422B2 (en) | 2017-06-01 | 2022-03-17 | Eisai R&D Management Co., Ltd. | Lewy body disease therapeutic agent containing pyrazoloquinoline derivative |
| WO2023064857A1 (en) | 2021-10-14 | 2023-04-20 | Incyte Corporation | Quinoline compounds as inhibitors of kras |
| CN114524827A (en) * | 2022-02-22 | 2022-05-24 | 深圳市儿童医院 | Pyrazole derivative for treating severe nervous disease and application thereof |
| CN114524828A (en) * | 2022-02-22 | 2022-05-24 | 深圳市儿童医院 | Thiazole derivative for treating severe nervous disease and application thereof |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5318759A (en) | 1976-08-02 | 1978-02-21 | Nisshin Oil Mills Ltd | Method of making fried beancurd |
| JPH05132484A (en) | 1991-04-26 | 1993-05-28 | Otsuka Pharmaceut Factory Inc | Pyrazoloquinoline and pyrazolonaphthylidene derivative |
| CA2189776A1 (en) | 1994-05-24 | 1995-11-30 | Bernd Buttelmann | Tricyclic dicarbonyl derivatives |
| HN2002000317A (en) | 2001-11-02 | 2003-05-21 | Pfizer | PDE9 INHIBITORS FOR TREATMENT OF CARDIOVASCULAR DISORDERS |
| EA200500322A1 (en) | 2002-08-07 | 2005-08-25 | Мицубиси Фарма Корпорейшн | COMPOUNDS OF DIHYDROPYRAZOLOPIRIDINE |
| DE10238722A1 (en) | 2002-08-23 | 2004-03-11 | Bayer Ag | Improving attention, concentration, cognition, learning and/or memory performance, using selective phosphodiesterase 9A inhibitors, preferably 4H-pyrazolo-(3,4-d)-pyrimidin-4-one derivatives |
| DE102004004142A1 (en) | 2003-05-09 | 2004-11-25 | Bayer Healthcare Ag | 6-Cyclylmethyl- and 6-alkylmethyl-substituted pyrazolopyrimidines |
| RU2426734C2 (en) | 2003-10-03 | 2011-08-20 | Зм Инновейтив Пропертиз Компани | Pyrazolopyridines and analogues thereof |
| US20060035920A1 (en) | 2004-05-28 | 2006-02-16 | Millennium Pharmaceuticals, Inc. | Chk-1 inhibitors |
| JP2006045118A (en) | 2004-08-04 | 2006-02-16 | Mochida Pharmaceut Co Ltd | New pyrazoloquinolone derivative |
| KR20080046728A (en) | 2005-09-15 | 2008-05-27 | 아스카 세이야쿠 가부시키가이샤 | Heterocyclic compound, and production process and use thereof |
| JPWO2008072778A1 (en) | 2006-12-13 | 2010-04-02 | あすか製薬株式会社 | Treatment for urinary tract diseases |
| CN101553491B (en) | 2006-12-13 | 2013-05-29 | Aska制药株式会社 | Quinoxaline derivative |
| ME00954B (en) * | 2007-05-11 | 2012-06-20 | Pfizer | Amino-heterocyclic compounds |
| UA105362C2 (en) | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
| US9079905B2 (en) | 2008-09-08 | 2015-07-14 | Boehringer Ingelheim International Gmbh | Compounds for the treatment of CNS disorders |
| TWI404721B (en) | 2009-01-26 | 2013-08-11 | Pfizer | Amino-heterocyclic compounds |
| ES2612954T3 (en) | 2009-03-05 | 2017-05-19 | Astellas Pharma Inc. | Quinoxaline Compounds |
| MY156377A (en) | 2009-03-31 | 2016-02-15 | Boehringer Ingelheim Int | 1-heterocycl-1, 5-dihydro-pyrazolo [3 , 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
| US8880976B2 (en) | 2009-09-25 | 2014-11-04 | Stmicroelectronics, Inc. | Method and apparatus for encoding LBA information into the parity of a LDPC system |
| JP2012005157A (en) * | 2010-06-14 | 2012-01-05 | Seiko Epson Corp | Method of manufacturing laminated component |
| GEP20156217B (en) | 2010-08-12 | 2015-01-12 | Boehringer Ingelheim Int | 6-cycloalkyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors |
| HUE028038T2 (en) | 2010-09-07 | 2016-11-28 | Astellas Pharma Inc | Pyrazoloquinoline compounds |
| US20130040971A1 (en) | 2011-02-14 | 2013-02-14 | Boehringer Ingelheim International Gmbh | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders |
| ES2527188T3 (en) | 2011-09-26 | 2015-01-21 | Sanofi | Pirazolquinolinone derivatives, their preparation and therapeutic use |
| JP6042060B2 (en) | 2011-09-26 | 2016-12-14 | サノフイ | Pyrazoloquinolinone derivatives, their preparation and therapeutic use |
| WO2013051639A1 (en) | 2011-10-07 | 2013-04-11 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Pyrazoloquinoline derivative |
| JP5666755B1 (en) | 2013-04-05 | 2015-02-12 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Salts and crystals of pyrazoloquinoline derivatives |
| AU2018278422B2 (en) | 2017-06-01 | 2022-03-17 | Eisai R&D Management Co., Ltd. | Lewy body disease therapeutic agent containing pyrazoloquinoline derivative |
| SG10202113198TA (en) | 2017-06-01 | 2021-12-30 | Eisai R&D Man Co Ltd | Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil |
| CA3059539A1 (en) | 2017-06-01 | 2018-12-06 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition comprising pde9 inhibitor |
| CN108563565B (en) | 2018-04-08 | 2021-12-17 | 中国人民解放军海军工程大学 | Method for establishing reliability quantitative analysis model of flight landing guidance system |
-
2018
- 2018-05-30 JP JP2019521250A patent/JP7177772B2/en active Active
- 2018-05-30 WO PCT/JP2018/020649 patent/WO2018221550A1/en active Application Filing
- 2018-05-30 AU AU2018276568A patent/AU2018276568A1/en active Pending
- 2018-05-30 EP EP18808870.2A patent/EP3632437B1/en active Active
- 2018-05-30 IL IL270394A patent/IL270394B/en unknown
- 2018-05-30 BR BR112019023595-7A patent/BR112019023595A2/en unknown
- 2018-05-30 CA CA3060183A patent/CA3060183A1/en active Pending
- 2018-05-30 SG SG10202113199RA patent/SG10202113199RA/en unknown
- 2018-05-30 US US16/607,459 patent/US11147803B2/en active Active
- 2018-05-30 KR KR1020197033123A patent/KR102627790B1/en active IP Right Grant
- 2018-05-30 CN CN201880030140.XA patent/CN110603039B/en active Active
- 2018-05-30 SG SG11201909590X patent/SG11201909590XA/en unknown
- 2018-05-30 MX MX2019013383A patent/MX2019013383A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR102627790B1 (en) | 2024-01-23 |
| SG11201909590XA (en) | 2019-11-28 |
| IL270394A (en) | 2020-02-27 |
| AU2018276568A1 (en) | 2019-11-07 |
| JPWO2018221550A1 (en) | 2020-04-02 |
| US11147803B2 (en) | 2021-10-19 |
| JP7177772B2 (en) | 2022-11-24 |
| BR112019023595A2 (en) | 2020-05-26 |
| EP3632437A1 (en) | 2020-04-08 |
| RU2019135838A3 (en) | 2021-09-29 |
| EP3632437A4 (en) | 2021-03-17 |
| CN110603039A (en) | 2019-12-20 |
| IL270394B (en) | 2022-08-01 |
| WO2018221550A1 (en) | 2018-12-06 |
| MX2019013383A (en) | 2020-02-20 |
| RU2019135838A (en) | 2021-07-13 |
| US20200129488A1 (en) | 2020-04-30 |
| KR20200010219A (en) | 2020-01-30 |
| EP3632437B1 (en) | 2024-03-13 |
| CA3060183A1 (en) | 2018-12-06 |
| CN110603039B (en) | 2023-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL275600A (en) | Exosomes for immuno-oncology and anti-inflammatory therapy | |
| IL265922A (en) | Tyk2 inhibitors and uses thereof | |
| IL271999A (en) | Tyk2 inhibitors and uses thereof | |
| SG10202113198TA (en) | Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil | |
| IL266109A (en) | Tyk2 inhibitors and uses thereof | |
| GB201709456D0 (en) | Therapeutic agents | |
| SG10202113199RA (en) | Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine | |
| EP3534910A4 (en) | Therapeutic agents and methods | |
| GB201711234D0 (en) | Pyrrolopyrimidine and pyrrolopyridine derivatives | |
| GB201617064D0 (en) | Compounds and their therapeutic use | |
| IL255530A (en) | Efflux-pump inhibitors and therapeutic uses thereof | |
| GB201715194D0 (en) | Compounds and their therapeutic use | |
| PL3565374T3 (en) | Region configuration methods and devices | |
| IL270011B (en) | Therapeutic compounds and methods | |
| GB201418809D0 (en) | Therapeutic agents and uses thereof | |
| PL3409659T3 (en) | Adamantane derivative and use thereof | |
| EP3120852A4 (en) | Prophylactic and/or therapeutic agent for immune diseases | |
| EP3701956A4 (en) | Prophylactic and/or therapeutic agent for dementia | |
| GB201700553D0 (en) | Therapeutic agents | |
| ZA202000959B (en) | Adamantylmethylamine derivative and use thereof as pharmaceutical | |
| IL270460B1 (en) | Novel compounds and therapeutic uses thereof | |
| IL282671A (en) | Therapeutic methods and compositions | |
| PL3476256T3 (en) | Bed system and use of the bed system | |
| GB201702921D0 (en) | Therapeutic agent | |
| GB201707076D0 (en) | Novel compounds and therapeutic uses thereof |